The interims to 30 June 2024 were in line with no surprises. However there have been several significant and positive post-period events such as the collaboration with Mölnlycke Health Care (MHC) and the proposed private placement that have added a dose of positive momentum to the stock. We believe that MHC will accelerate adoption of Steriwave in multiple geographies. The key value creation driver is the pivotal US Phase 3 trial which still requires funding, with the company exploring funding options. We adjust our forecasts to reflect the trial delay and believe that the Company is well positioned to deliver upon its promises.
